Literature DB >> 28257599

Immunosuppressive drugs affect interferon (IFN)-γ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis.

C R Grant1, B S Holder1,2, R Liberal1,3, M A Heneghan1, Y Ma1, G Mieli-Vergani1,4, D Vergani, M S Longhi1,5.   

Abstract

Autoimmune hepatitis (AIH) is characterized by overwhelming effector immune responses associated with defective regulatory T cells (Tregs ). Several lines of evidence indicate CD4 as the main effectors involved in autoimmune liver damage. Herein we investigate the in-vitro effects of prednisolone, 6-mercaptopurine, cyclosporin, tacrolimus, mycophenolic acid (MPA) and rapamycin, immunosuppressive drugs (ISDs) used in AIH treatment, on the expression of proinflammatory cytokines, co-inhibitory molecules and ability to proliferate of CD4+ CD25- cells, isolated from the peripheral blood of treatment-naive patients with AIH. We note that in healthy subjects (HS) following polyclonal stimulation and in the absence of ISDs, the expression of interferon (IFN)-γ, interleukin (IL)-17 and tumour necrosis factor (TNF)-α by CD4 effectors peaks at 48 h and decreases at 96 h to reach baseline levels. In contrast, in AIH the expression of all these proinflammatory cytokines continue rising between 48 and 96 h. Levels of programmed cell death-1 (PD-1), T cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) and cytotoxic T lymphocyte antigen-4 (CTLA-4) increase over 96-h culture both in HS and AIH, although with faster kinetics in the latter. Exposure to ISDs contains IFN-γ and PD-1 expression in AIH, where control over CD4+ CD25- cell proliferation is also noted upon exposure to MPA. Treatment with tacrolimus and cyclosporin render CD4+ CD25- cells more susceptible to Treg control. Collectively, our data indicate that in treatment-naive patients with AIH, all ISDs restrain T helper type 1 (Th1) cells and modulate PD-1 expression. Furthermore, they suggest that tacrolimus and cyclosporin may ameliorate effector cell responsiveness to Tregs .
© 2017 British Society for Immunology.

Entities:  

Keywords:  autoimmune hepatitis; co-inhibitory molecules; effector T cells; immunosuppressive drugs; proinflammatory cytokines

Mesh:

Substances:

Year:  2017        PMID: 28257599      PMCID: PMC5461095          DOI: 10.1111/cei.12956

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

Review 1.  Molecular mechanisms of glucocorticoid action: what is important?

Authors:  R Newton
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

2.  Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis.

Authors:  Maria Serena Longhi; Munther J Hussain; Ragai R Mitry; Sunil K Arora; Giorgina Mieli-Vergani; Diego Vergani; Yun Ma
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

Review 3.  Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.

Authors:  S N Sehgal
Journal:  Clin Biochem       Date:  1998-07       Impact factor: 3.281

4.  Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis.

Authors:  H Mizuhara; M Uno; N Seki; M Yamashita; M Yamaoka; T Ogawa; K Kaneda; T Fujii; H Senoh; H Fujiwara
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

5.  The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.

Authors:  Yanyan Qu; Baojun Zhang; Liang Zhao; Guangwei Liu; Haixia Ma; Enyu Rao; Chun Zeng; Yong Zhao
Journal:  Transpl Immunol       Date:  2007-01-24       Impact factor: 1.708

6.  Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease.

Authors:  Maria Serena Longhi; Yun Ma; Dimitrios P Bogdanos; Paul Cheeseman; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Hepatol       Date:  2004-07       Impact factor: 25.083

Review 7.  Autoimmune hepatitis: a comprehensive review.

Authors:  Rodrigo Liberal; Charlotte R Grant; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Autoimmun       Date:  2012-12-04       Impact factor: 7.094

8.  Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells.

Authors:  Maria Serena Longhi; Ragai R Mitry; Marianne Samyn; Astrid Scalori; Munther J Hussain; Alberto Quaglia; Giorgina Mieli-Vergani; Yun Ma; Diego Vergani
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

9.  Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression.

Authors:  Li Zhao; Yanli Tang; Zhengrui You; Qixia Wang; Shuwen Liang; Xiaofeng Han; Dekai Qiu; Jue Wei; Yuan Liu; Lei Shen; Xiaoyu Chen; Yanshen Peng; Zhiping Li; Xiong Ma
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

10.  Liver FOXP3 and PD1/PDL1 Expression is Down-Regulated in Chronic HBV Hepatitis on Maintained Remission Related to the Degree of Inflammation.

Authors:  Georgios Germanidis; Nikoletta Argentou; Prodromos Hytiroglou; Themistoklis Vassiliadis; Kalliopi Patsiaoura; Anastasios E Germenis; Matthaios Speletas
Journal:  Front Immunol       Date:  2013-07-25       Impact factor: 7.561

View more
  8 in total

1.  Mycophenolate Mofetil Protects Septic Mice via the Dual Inhibition of Inflammatory Cytokines and PD-1.

Authors:  Shun-Wei Huang; Hao Chen; Mei-Ling Lu; Jin-Long Wang; Rong-Li Xie; Bing Zhao; Ying Chen; Zhi-Wei Xu; Jian Fei; En-Qiang Mao; Er-Zhen Chen
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

2.  Tryptophan-kynurenine profile in pediatric autoimmune hepatitis.

Authors:  Simon D Lytton; Marcin Osiecki; Bożena Cukrowska; Aldona Wierzbicka; Maria Goliszek; Piotr Socha; Wojciech Janczyk; Dilek Dayanakli; Dieter Abendroth; Sabine Kramp; Kai Fechner; Thomas Scheper; Michael Mahler; Chelsea Bentow; Dimietrios Bogdanos; Dietmar Fuchs; Marek Woynarowski
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

3.  Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis.

Authors:  Rodrigo Liberal; Charlotte R Grant; Muhammed Yuksel; Jonathon Graham; Alireza Kalbasi; Yun Ma; Michael A Heneghan; Giorgina Mieli-Vergani; Diego Vergani; Maria Serena Longhi
Journal:  Hepatology       Date:  2017-10-03       Impact factor: 17.425

Review 4.  Regulatory T cells in autoimmune hepatitis: an updated overview.

Authors:  Maria Serena Longhi; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Autoimmun       Date:  2021-02-27       Impact factor: 7.094

5.  Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation.

Authors:  Pietro Merli; Ignazio Caruana; Rita De Vito; Luisa Strocchio; Gerrit Weber; Francesca Del Bufalo; Vanessa Buatois; Paolo Montanari; Maria Giuseppina Cefalo; Angela Pitisci; Mattia Algeri; Federica Galaverna; Concetta Quintarelli; Valentina Cirillo; Daria Pagliara; Walter Ferlin; Maria Ballabio; Cristina De Min; Franco Locatelli
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

Review 6.  Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer.

Authors:  Yara O Aghabi; Alia Yasin; James I Kennedy; Scott P Davies; Amber E Butler; Zania Stamataki
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 8.786

7.  Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management.

Authors:  Michele May-Sien Tana; Arielle Klepper; Amy Lyden; Angela Oliveira Pisco; Maira Phelps; Breann McGee; Kelsey Green; Sandy Feng; Joseph DeRisi; Emily Dawn Crawford; Craig S Lammert
Journal:  PLoS One       Date:  2022-03-21       Impact factor: 3.240

8.  Association of Serum T cell Immunoglobulin Domain and Mucin-3 and Interleukin-17 with Systemic Lupus Erythematosus.

Authors:  Lairun Jin; Ran Bai; Jun Zhou; Wei Shi; Liang Xu; Jun Sheng; Hui Peng; Yuelong Jin; Hui Yuan
Journal:  Med Sci Monit Basic Res       Date:  2018-10-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.